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Human glycolytic enzyme α-enolase was associated with human diseases and with inﬂammation. An ELISA test was developed
to measure anti-α-enolase AAE IgG and AAE IgA in the serum from patients aﬀected by inﬂammatory diseases with the purpose
to evaluate it as a novel diagnostic marker. 80 healthy blood donors and 194 paediatric patients aﬀected by Juvenile idiopathic
arthritis (JIA), celiac disease (CD), Crohn’s Disease (CrD), hereditary periodic fever (HPF), and PFAPA syndrome were included
in the study. HPF patients showed high levels of AAE antibodies, whereas JIA, CD, and CrD presented only partial results. Benign
fevers such as PFAPA were almost negative for AAE Abs. These ﬁndings suggested that the genetic dysfunction of inﬂammasome
associated with HPF could lead to the formation of AAE Abs that could be used for an early and easy diagnosis.
1.Introduction
The human glycolytic enzyme α-Enolase was previously
associated with human diseases (i.e., Crohn’s disease and
Systemic Lupus Erythematosus), as a novel autoantigen with
an unknown pathologic signiﬁcance other than tissue dam-
age, or cross-reactivity after a contact with bacterial or yeast
enolase [1–6].
α-Enolase undergoes a posttranslational modiﬁcation
known as arginine deimination or citrullination by peptidyl-
arginine-deiminase (PAD). Anticitrullinated α-Enolase anti-
bodies were found in serum of diﬀerent immune dis-
eases, that is, rheumatoid arthritis (RA), multiple sclerosis,
Alzheimer’s disease, and psoriasis [7–9].
Recently it was shown that during the inﬂammatory
process, α-Enolase, together with other glycolytic enzymes,
might be a substrate of caspase-1 in the newly described
caspase-1digestosome[10].Caspase-1leadstotheactivation
of IL-1β and NF-kB, through the inﬂammasome, and also
to the inﬂammatory cell death called pyroptosis. Pyroptosis,
eliminating macrophages, probably contributes to the end of
inﬂammation. Because glycolysis is essential for macrophage
survival and activation, the cleavage of α-Enolase and the
glycolysis substrates, which results in reduction of cellular
glycolysis,seemstobeanessentialsteptowardcelldeath[10].
We hypothesized that high amount of α-Enolase-derived
peptides and/or their ineﬃcient removal from the milieu
could be immunogenic and that high amount of antibodies
anti-α-enolase could be an epiphenomenon in inﬂammatory
processes that are characterized by an important caspase-1
activation. The evaluation ofantibodies anti-α-enolase (AAE
Abs) couldprovide a novel tool forbetter deﬁnition of diﬀer-
ential diagnosis in patients with inﬂammatory disorders.
For this purpose we set up an Enzyme-Linked Immune
Sorbent Assay (ELISA) to evaluate serum anti-α-enolase
antibodies (AAE Abs) in pediatric healthy controls and
patients aﬀected by chronic inﬂammatory conditions due
to diﬀerent ethiopathogenesis: Juvenile idiopathic arthritis2 International Journal of Rheumatology
(JIA), celiac disease (CD), Crohn’s disease (CrD), and peri-
odic fevers, namely chronic infantile neurologic cutaneous
and articular (CINCA) syndrome, mevalonate kinase deﬁ-
ciency (MKD), Familial Mediterranean fever (FMF), TNF-R
associated periodic syndrome (TRAPS), and periodic fever
associated to aphthous, pharyngitis, and cervical adenop-
athies (PFAPA).
2.MaterialsandMethods
2.1. Patients. 194 sera from children and adolescents with a
diagnosisofinﬂammatorydiseasewereincludedinthestudy.
31 patients are aﬀected with Juvenile Rheumatoid Arthritis
(11 males/20 female; 11.2 years ± 4 standard deviation,
SD), 55 with celiac disease (17 males/38 females; 12.7 ±
11.3), 59 with Crohn’s disease (33 male/26 female; 11.9 ±
5.1), 20 with hereditary periodic fever (HPF; 13 male/7
female; 12.6 ± 8.1), and 28 with PFAPA syndrome (PFAPA;
13male/15female; 3.4 ± 2.7). The group of HPF consists of
9 CINCA syndrome, 5 FMF, 5 MKD and 1 TRAPS.
184 patients were recruited from the Paediatric Division
of the Institute of Maternal and Child Health IRCCS “Burlo
Garofolo” (Trieste, Italy) and 10 (5 FMF and 5 CINCA) from
the IIPaediatric Division of the Institute of Child Health
IRCCS“G.Gaslini”(Genoa,Italy).Alltheserawerecollected
at the moment of the diagnosis, before starting any kind of
treatment.
JIA was diagnosed according to the criteria of the
International League of Associations for Rheumatology [11].
The CD diagnosis was based on the evaluation of clinical
features, ELISA anti-transglutaminase antibody (tTG) quan-
tiﬁcation (Eu-tTG kit, Eurospital, Trieste, Italy), and the
presence of the HLA DQ2/DQ8 heterodimer (Eu-Gen Risk,
Eurospital) and conﬁrmed by intestinal biopsy following
the indications recommended by the European Society for
Paediatric Gastroenterology, Hepatology and Nutrition [12].
CrD was diagnosed according to clinical, endoscopic, and
histologic criteria, as suggested by international guidelines
[13]. HPFs were diagnosed according to clinical parameters
speciﬁcally related to each kind of disease [14]a n dt o
the molecular analysis of respective genes (CINCA syn-
drome: CIAS1/NALP3; FMF: MEFV; MKD MVK; TRAPS:
TNFRS1A). PFAPA syndrome was diagnosed by the meaning
of clinical signs [15] and after the exclusion of any HPF by
the meaning of the analysis of the HPF genes.
V i r a lo rp a t h o g e ni n f e c t i o n sa sw e l la sc a n c e rh a v eb e e n
previously excluded.
Moreover, 80 healthy Italian subjects (35 males/45 fe-
males; mean age 7.1years ± 4.8 SD) matched for age and
ethnicity with the patients, and not related to the patients
group, were included as controls (HC). One patient aﬀected
by vasculitis was also included as positive control [16].
The study protocol was approved by independent ethics
committees at each study site. Patients or their parents pro-
vided written informed consent.
2.2. ELISA for Anti-α-enolase IgG and IgA Antibodies. Two
ELISA tests were developed using recombinant α-Enolase
Table 1: Patients and controls demographic data. Mean age and
males/female ratio were reported for healthy controls (HC) and
in patients with juvenile idiopathic arthritis (JIA), celiac disease
(CD), Crohn’s disease (ChD), hereditary periodic fevers (HPFs),
and PFAPA syndrome (PFAPA). Age and males/females ratio from
patients were compared with HC using an independent t-test and a
Fisher exact test, respectively.
Age (years;
mean ± SD) P Males/females
ratio P
HC (n = 80) 7.1 ± 4.8 35/45
JIA (n = 31) 11.2 ±4 0.12 11/20 0.52
CD (n = 55) 12.7 ± 11.3 0.31 17/38 0.15
CrD (n = 59) 11.9 ±5.1 0.10 33/26 0.17
HPF (n = 20) 12.6 ±8.1 0.14 13/7 0.13
PFAPA (n = 29) 3.4 ± 2.7 0.08 13/15 0.83
(a gift from Dr. Edomi; University of Trieste) as the capture
reagent to detect AAE IgA or AAE IgG serum antibodies.
Phosphatase-conjugatedanti-humanIgAoranti-humanIgG
(Sigma Aldrich) were used as the detection antibody.
Microtiter plates (96-well Nunc Maxisorp)w e r ec o a t e d
withpuriﬁedunlabelledrecombinantα-Enolaseat9.5μg/mL
in PBS overnight at 4◦C. Plates were then washed with 0.05%
Tween-20 in PBS (wash buﬀer) and saturated with 0.1%
Tween-20 in PBS for 20◦Ca tr o o mt e m p e r a t u r e( R T ) .
The ELISA was performed by diluting healthy controls
and patients serum 1:100 in PBS for IgG test and 1:200
for IgA test. The serum from children aﬀected by vasculitis
w a su s e da sp o s i t i v ec o n t r o la sp r e v i o u s l yr e p o r t e d[ 16]. All
incubations were performed at RT, and all volumes were
100μl per well. The plates were incubated for 1hour and
washed three times with wash buﬀer.
The phosphatise-conjugated anti-human IgA (diluted
1:2000; Sigma Aldrich) or anti-human IgG (diluted 1:2000;
Sigma Aldrich) was then added to the wells, incubated for
1hour, and plates were washed three times. The assay was
developed by the addition of 1g/L p-nitrophenyl phosphate
(Sigma Aldrich) to the plate. The data was acquired by mea-
suring absorbance at 405nm and analysed using GraphPad
Prism version 5.0. Results were expressed as arbitrary unit
(AU)/mL.
2.3. Data Analysis. Statistical analysis was carried out using
the GraphPad Prism software version 5.0. For the compari-
son of groups, independent Student t-test and ANOVA with
Scheﬀe’s post hoc test were used. P values of less than 0.05
were regarded as signiﬁcant.
3. Results
Demographic characteristics (mean age, male/female ratio)
were compared between healthy controls (HCs) and each
group of patients and data were reported in Table 1.
80 sera from healthy blood donors included as controls
were tested for the presence of AAE IgA and IgG antibodies.International Journal of Rheumatology 3
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Figure 1: Levels of anti-α-enolase antibodies ((a): IgG; (b):IgA) in patients with juvenile idiopathic arthritis (JIA), celiac disease (CD),
Crohn’s disease (CrD), hereditary periodic fevers (HPF), PFAPA syndrome (PFAPA), and vasculitis (V) and healthy controls (HC). Results
are expressed as arbitrary units per mL (AU/mL). Cut-oﬀ values are indicated with a dashed line. Patients’ antibody levels are compared to
healthy control by t-test (∗∗ = P < 0,001, ∗ = P < 0,05).
The mean and standard deviation (SD) was 15.44 UA/mL ±
5.21 for AAE IgA and 16.79 UA/mL ± 5.81 for AAE IgG.
The cut-oﬀ values calculated for each Ig class (mean +
2SD) were 25.86 and 28.41, respectively.
The results for the vasculitis patient serum were
29.92AU/mL for AAE IgA and 54.08AU/mL for AAE IgG.
A larger number of serum samples from patients with
chronic inﬂammatory diseases were procured to test the
utility of the ELISA in detecting AAE antibodies.
Samples of sera from 194 paediatric patients aﬀected by
JIA (n = 31), CD (n = 55), CrD (n = 59), HPF (n = 20), and
PFAPA (n = 29) were compared with the controls sera.
The mean and standard deviation of each group for the
assays were as follows: JIA IgA: 31.21 ± 22.11; IgG: 42.52 ±
13.28,forCD25.72±24.74;34.23±12.42,CrD29.60±16.69;
43.04±18.39,forHPF37.41±34.51;46.57±21.21,forPFAPA
11.59 ± 7.87; 14.09 ± 6.46 (Table 1). Using the unpaired t-
test (2-tailed) method to evaluate the diﬀerence between the
HC and patient sera groups, the diﬀerences as follow: each
comparisonwereHCversusJIAIgA:P = 4.4exp−4;IgG:P =
3.43exp−12, for HC versus CD P = 0.004; P = 1.28exp−14,
for HC versus CrD P = 2.81exp−8; P = 6.7exp−16, for HC
versus HPF P = 0.01; P = 8.43exp−6, for HC versus PFAPA
P = 0.02; P = 0.05 (Table 2).
Among the patient groups signiﬁcant diﬀerences were
reported for PFAPA versus all the other groups as AAE IgA
and IgG, JIA versus CD (IgG: P = 0.006), CD versus CrD
(IgG: P = 0.003), and CrD versus HPF (IgG: P = 0.025) (See
Supplementary Data S1 in supplementary material available
online at doi: 10.1155/2011/870214).
Furthermore, using the cut-oﬀ values of 25.86 AU/mL
for IgA, 52% (16 of 31 samples) of JIA, 33% (18/55) of CD,
53% (31/59) of CrD, 65% (13/20) of HPF, and 4% (1/29) of
PFAPA sera were above the cut-oﬀ (AAE IgA+) (Figure 1(a),
Table 2).
87% (27/31) of JIA, 65% (36/55) of CD, 75% (44/59)
of CrD, 80% (16/20) of HPF, and 4% (1/29) PFAPA sera
were above the IgG cut-oﬀ of 28.41 AU/mL (AAE IgG+)
(Figure 1(b), Table 2). 16 out of 31 JIA (52%), 15 out of 55
CD(27%),24outof59CD(41%),and1outof20HPF(5%)
were both AAE IgA+ and AAE IgG+ (Table 2).
Overall, the samples represent an average of 41% positive
AAE IgA and 64% AAE IgG above the cut-oﬀs established
for the assay. Despite the high speciﬁcity of the AAE Abs
test (100% for IgA and IgG), the sensitivity varied within the
cohorts ranging from 33 to 65% for AAE IgA and from 65
to 87% for AAE IgG (Table 2). These results show that the
AAE ELISA can distinguish diﬀerences between serum from
healthydonorsandpatientswithanimportantinﬂammatory
disease.
When patients aﬀected by JIA were stratiﬁed for joint
involvement and severity of the disease (polyarticular, pau-
ciarticular, and systemic JIA) a signiﬁcant diﬀerence was
observed for AAE IgA titre in polyarticular JIA versus HC
(P = 2.0exp−4) and poliarticular JIA versus systemic JIA
(P = 0.004);forAAEIgGallthesubgroupsweresigniﬁcantly
diﬀerent compared to HC (Table 3).
13 out of 16 patients with pauci-articular JIA were AAE
IgG+ (81%) and 7 were AAE IgG+ IgA+ (44%). 9 out of
10 subjects with a poliarticular JIA were AAE IgG+ (90%)
and 8 AAE IgG+ IgA+ (80%). The 5 patients with systemic
arthritis were AAE IgG+ (100%), and only 1 out of 5 was
AAEIgG+IgA+(20%)(Table 3).TheAAEevaluationdidnot
vary according to the clinical manifestation of JIA, with the
only exception of AAE IgA level that is signiﬁcantly higher in
pol y articularc o mpar edt osy st e micJIA(P =0.035) (Table 3).
Among the group of hereditary periodic fever, 67% of
CINCA patients (6/9) were AAE IgA+ and all the 9 CINCA
patients (100%) were AAE IgG+. 80% (4/5) of FMF were
both AAE IgA+ IgG+, and 20% (1/5) were double negative
for the test. 60% (3/5) of MKD were AAE IgA+, 60% (3/5)
were AAE IgG+, and 40% (2/5) were AAE IgA+ IgG+.
The results of 1 MKD patient, to note the one with the
most severe clinical presentation, were fully negative. The4 International Journal of Rheumatology
Table 2: AAE IgA and AAE IgG in healthy controls and patients. Levels and percentage of positivity of anti-α-enolase IgA and IgG in healthy
controls (HCs) and patients with juvenile idiopathic arthritis (JIA), celiac disease (CD), Crohn’s disease (ChD), hereditary periodic fevers
(HPF), and PFAPA syndrome (PFAPA) were reported as mean and standard deviation (SD). AAE levels are expressed as arbitrary units per
mL (AU/mL) and AAE positivity as number and percentage of sera with titre above the cut-oﬀ. Patients’ AAE levels are compared to healthy
control by t-test and P values are reported.
AAE IgA AAE IgA+ P AAE IgG AAE IgG+ P
HC (n = 80) 15.44 ±5.21 0 16.79 ±5.81 0
JIA (n = 31) 31.21 ±22.11 16 (52%) 4.4exp−44 2 .52 ±13.28 27 (87%) 3.4exp−12
CD (n = 55) 25.72 ±24.74 18 (33%) 0.004 34.23 ±12.42 36 (65%) 1.3exp−14
CrD (n = 59) 29.60 ±16.69 31 (53%) 2.8exp−84 3 .04 ±18.39 44 (75%) 6.7exp−16
HPF (n = 20) 37.41 ±34.51 13 (65%) 0.01 46.57 ±21.21 16 (80%) 8.4exp−6
PFAPA (n = 29) 11.59 ±7.87 1 (4%) 0.02 14.09 ±6.46 1 (4%) 0.05
TRAPS patient serum resulted in being negative for the AAE
detection.AlsointhiscohorttheELISAresultsdidnotreport
any signiﬁcant diﬀerence within the 4 HPFs (Table 3).
4. Discussion
This study showed that autoantibodies directed against
human α-Enolase are present in diﬀerent inﬂammatory
conditions in paediatric patients, such as juvenile idiopathic
arthritis, celiac disease, Crohn’s disease, and hereditary peri-
odicfevers,butnotinbenignfeverPFAPA.Initiallydescribed
as diagnostic marker for rheumatoid arthritis (RA), AAE
antibodies seem to occur in several inﬂammatory disorders
[17], lacking the proposed role of speciﬁc diagnostic test for
RA.
As previously reported for RA in adults, AAE antibodies
were present in JIA. In particular, AAE IgG was found in
87% of JIA sera (Table 2) in respect to 25% and 6% of
positivity in RA sera demonstrated with immune-blotting
technique by other authors [18, 19] .T h er a t eo fp o s i t i v e
sera among our paediatric group was particularly high in
the systemic presentation of the disease (AAE IgG 100%),
whereas AAE IgA levels were more heterogeneous (Table 3).
Although JIA does not present mucosa involvement, these
results could be explicated taking in account a hypothesis
of polyclonal activation in this inﬂammatory disease with
autoimmune etiopathology, as described by other authors
[17]. Moreover the presence of AAE Abs did not correlate
with a bad prognosis for patients with JIA as suggested by
Saulot in early rheumatoid arthritis [19], even if we could
only observe patients in a short follow-up period (6–12
months).
AAE antibodies were previously described, with a pro-
teomic approach, in adults aﬀected by celiac disease [5]a n d
by inﬂammatory bowel disease [20]. In celiac subjects we
observed a low titre of AAE IgA (33%) and a quite elevated
one of AAE IgG (65%) (Table 2). This suggests that the
activation of autoreactive B cells against α-Enolase could be
not mucosa speciﬁc, but perhaps a systemic event.
74% of Crohn’s patients presented AAE IgG compared
to data reported by Vermeulen et al. (AAE IgG 50%) [20],
highlightingthemassiveinﬂammatorystateofthesesubjects.
These results conﬁrm previously reported ﬁndings about
the presence of AAE Abs in the serum of patients aﬀected by
important inﬂammatory conditions, although the variable
sensitivity of the test does not sustain our initial enthusiasm.
For the ﬁrst time to our knowledge AAE antibodies were
described in subjects aﬀected by recurrent fevers. Our results
clearly showed a diﬀerence between benign fever PFAPA,
which was almost negative for AAE Abs, and hereditary
periodic fevers (Table 2). Moreover, among the HPFs, the
ones characterized by a genetic defect in inﬂammasome—
such as CINCA syndrome and Familial Mediterranean
fever—are more frequently positive for the test (Table 3).
Hereditary periodic fevers represent a big diagnostic
challenge due to the wide and often unspeciﬁc clinical
spectrum that accounts for possible diﬃculties in diﬀerential
diagnosis with chronic inﬂammatory disorders and also with
the benign PFAPA syndrome. However an early diagnosis is
very important in these conditions to start the appropriate
treatmentandtopreventunwantedlong-termcomplications
in HPF or, on the other hand, to rapidly exclude a
severe disease in PFAPA and avoid inappropriate and often
expensive investigations. For this reason, despite the limited
size of our cohorts, we believe that AAE antibodies titre
could be a novel useful inﬂammatory marker for these rare
syndromes.
Finally, our ﬁndings are interesting also considering their
ethiopathologic implications. The quite diﬀerent levels of
anti-α-enolase antibodies that we found in our patients seem
to support our hypothesis that the immunogenicity of α-
Enolase could be a characteristic event in caspase-1-related
diseases. We underlined that the highest AAE Abs levels were
observedinCINCAsyndrome,FamilialMediterraneanfever,
and the inﬂammasome-related syndromes. HIDS patients
presented high AAE Abs, and this disease was recently
associated with the autoactivation of caspase-1, too [21].
Moreover,one of themost known susceptibility genesfor
Crohn’s disease is NOD2. NOD2 belongs to the NOD-Like
Receptor (NLR) superfamily comprising also CIAS1/NALP3
(mutated in CINCA syndrome). NOD2 induces NF-kB,
similarly to inﬂammasome, and it was supposed to activate
caspase-1 interacting with NALP1 [22], so it is possible
that the 2 signalling cascades (inﬂammasome and NOD-
some), could converge and aﬀect the same molecular targets,
such as glycolytic enzymes destruction before cell death.
A dysfunction in inﬂammasome was also hypothesized for
early rheumatoid arthritis [23] and celiac disease [24]b u tInternational Journal of Rheumatology 5
Table 3: Serum level and percentage of AAE IgA+ and AAE IgG+ in JIA stratiﬁed for clinical presentation and in HPF classiﬁed for genetic
defect. Levels of anti-α-enolase IgA and IgG in patients with pauciarticular, polyarticular, or systemic juvenile idiopathic arthritis (JIA)
CINCA syndrome, FMF, MKD, and TRAPS hereditary periodic fevers (HPF) were reported as mean and standard deviation (SD). Results
are expressed as arbitrary units per mL (AU/mL). Patients’ AAE levels are compared by t-test (∗ = P < 0.05). Percentage of AAE IgA and IgG
positivity in each disease class is also reported.
AAE IgA (mean + SD) AAE IgG (mean + SD) IgA+ IgG+ IgA+ IgG+
JIA
JIA-pauci (n = 16) 30.09 ±28.77 39.75 ±13.20 7 (44%) 13 (81%) 7 (44%)
JIA-poly (n = 10) 36.98 ±11.62∗ 49.09 ±14.59 8 (80%) 9 (90%) 8 (80%)
JIA-syst (n = 5) 23.26 ±10.0∗ 38.23 ±5.38 1 (20%) 5 (100%) 1 (20%)
HPF
CINCA (n = 9) 29.58 ±16.47 55.06 ±12.81 6 (67%) 9 (100%) 6 (67%)
FMF (n = 5) 49.30 ±43.43 48.43 ±29.16 4 (80%) 4 (80%) 4 (80%)
MKD (n = 5) 45.33 ±51.28 36.52 ±21.99 3 (60%) 3 (60%) 2 (40%)
TRAPS (n = 1) 8.77 12.97 — — —
with discordant results. For PFAPA syndrome several studies
were made to elucidate the genetic association with known
inﬂammatory genes, but without any ﬁndings. Considering
its benign clinical presentation, its good prognosis, and the
lack of association with any known inﬂammatory gene,
nowadays PFAPA syndrome is not included in hereditary
autoinﬂammatory disorders. We hypothesized that in these
patients the inﬂammasome pathway and caspase-1 are still
untouchedandforthisreasonthepathologiceventsthatlead
to the high production of AAE Abs do not occur.
In conclusion, paediatric patients aﬀected by hereditary
periodic fevers showed high levels of AAE Abs; JIA, Crohn’s
disease, and celiac disease presented only partial results,
whereas benign fevers such as PFAPA were almost negative.
Although our results are quite preliminary and obtained
with a yet unvalidated technique and need further investiga-
tion as well as analyses performed on more numerically con-
sistent cohorts of healthy controls and patients, we believe
that AAE Abs evaluation could represent a quite cheap and
fast way to characterize subjects with an important inﬂam-
matory disregulation, especially in a diﬀerential diagnosis
between hereditary periodic fevers and benign fever such as
PFAPA syndrome. For these auto-inﬂammatory syndromes
the only speciﬁc laboratory investigation is the mutational
screening in candidate genes, which is time-spending and
expensive, especially considering that, in particular in the
ﬁrst years of life, recurrent fevers—variably associated with
abdominal involvement and lymphadenopathy—are often
present in children and they do not ever represent a genetic
disease.
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